MS drug sickens patient...again
Another case of a potentially fatal brain infection has been reported in a patient taking the multiple sclerosis drug Tysabri, the biotech who developed the drug announced yesterday. This is the fourth case of infection, called progressive multifocal leukoencephalopathy (PML) this year. They are the only cases reported since the drug was taken off the market in 2005 because of three cases of infection. The FDA allowed Tysabri back on the market in 2006 with restrictions and stronger warnings.
Written byAndrea Gawrylewski
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
**__Related stories:__***linkurl:Fine-tuning our defenses;http://www.the-scientist.com/2007/05/01/s56/1/
[May 2007]*linkurl:The art of adapting to MS;http://www.the-scientist.com/2007/05/01/s6/1/
[May 2007]*linkurl:Embryonic origins of autoimmunity;http://www.the-scientist.com/blog/display/54377/
[26 February 2008]
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Meet the Author
This person does not yet have a bio.View Full Profile
Share
